Alkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in the United States, Ireland and internationally. The company is headquartered in Dublin, Ireland.
| Revenue (TTM) | $1.75B |
| Gross Profit (TTM) | $1.53B |
| EBITDA | $281.69M |
| Operating Margin | 13.90% |
| Return on Equity | -0.02% |
| Return on Assets | 3.71% |
| Revenue/Share (TTM) | $10.53 |
| Book Value | $11.10 |
| Price-to-Book | 4.01 |
| Price-to-Sales (TTM) | 4.40 |
| EV/Revenue | 4.733 |
| EV/EBITDA | 46.46 |
| Quarterly Earnings Growth (YoY) | -81.60% |
| Quarterly Revenue Growth (YoY) | 21.80% |
| Shares Outstanding | $168.04M |
| Float | $155.45M |
| % Insiders | 1.40% |
| % Institutions | 107.53% |
Volatility is currently contracting
Alkermes NASDAQ: ALKS reported third-quarter 2026 results marked by 31% year-over-year growth in proprietary product sales, while management highlighted continued investment in its orexin development portfolio across sleep, neuropsychiatric and neurological disorders.
Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alkermes (ALKS) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to earnings of $0.49 per share a year ago.
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants in adult participants with major depressive disorder (MDD). ALKS 7290 is the company's investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD) and for the adjunctive treatment of MDD. “Orexin biology represents a compelling are.
Alkermes is maintained at a 'Buy' with a $57 price target, driven by LUMRYZ's commercial momentum and a promising neuroscience pipeline. 3Q26 revenue is projected to rise 18% year-over-year but decline sequentially, with adjusted EPS expected to fall 64.3% due to elevated R&D and SG&A expenses. LUMRYZ's patient growth and LYBALVI's prescription trends are key near-term metrics, while Alixorexton's clinical progress bolsters long-term investment appeal.
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the company's third quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webca.
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
LQDA's Yutrepia drives rapid growth, while ALKS benefits from a diversified portfolio, Lumryz and a broader pipeline.
ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ALKS and any ticker you trade — then tracks every position and per-strategy win rate.
